New “more powerful and effective” drug than its predecessor
According to the professor, health care in our country is so good that practically no children die from the effects of the RS virus. “But an IC registration obviously has a big impact. In addition, the virus can cause long-term respiratory ailments,” says Van Woensel.
–
In countries where healthcare is less in order, the impact is even greater. According to the professor, thousands to tens of thousands of children in poor countries are dying from the effects of the RS virus.
–
Research has shown that the new drug is safe. According to Van Woensel, it is more potent and effective than Palivizumab, a comparable drug. “Also, Palivizumab has the disadvantage of having to inject it every month. Nirsevimab requires an injection and works for three months.”
–
RIVM expects the RS vaccine within five years
RIVM virologist Adam Meijer is also pleased with the developments surrounding Nirsevimab. “This will particularly benefit children in their first year of life.” According to him, it seems that the drug may soon be given to all children. In the period between their birth and the next RS season.
–
When the injected antibody wears off, the protection is over. The body does not create its own immunity. But “because the risk of complications after an RS infection is higher in the first year of life, the drug is a good option,” says Meijer.
–
Meanwhile, a lot of work is also being done on various RS vaccines. These potential vaccines are still in various stages of testing. The RIVM virologist predicts that an RS vaccine may become available within five years.
–
